NetraMark Holdings (XCNQ:AIAI) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NetraMark Holdings FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. NetraMark Holdings's Free Cash Flow for the three months ended in Dec. 2023 was C$-0.96 Mil. NetraMark Holdings's Revenue for the three months ended in Dec. 2023 was C$0.00 Mil. Therefore, NetraMark Holdings's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, NetraMark Holdings's current FCF Yield % is -7.22%.

The historical rank and industry rank for NetraMark Holdings's FCF Margin % or its related term are showing as below:

XCNQ:AIAI' s FCF Margin % Range Over the Past 10 Years
Min: -4362.83 Med: -3524.11 Max: -1473.86
Current: -1473.86

During the past 4 years, the highest FCF Margin % of NetraMark Holdings was -1473.86%. The lowest was -4362.83%. And the median was -3524.11%.

XCNQ:AIAI's FCF Margin % is ranked worse than
97.89% of 663 companies
in the Healthcare Providers & Services industry
Industry Median: 1.44 vs XCNQ:AIAI: -1473.86

NetraMark Holdings FCF Margin % Historical Data

The historical data trend for NetraMark Holdings's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NetraMark Holdings FCF Margin % Chart

NetraMark Holdings Annual Data

Trend

Sep20

Sep21

Sep22

Sep23

FCF Margin %

-4,362.83

-2,685.39

NetraMark Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial									-360.53	-56,200.00	-385.23	-	-

Competitive Comparison of NetraMark Holdings's FCF Margin %

For the Health Information Services subindustry, NetraMark Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NetraMark Holdings's FCF Margin % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, NetraMark Holdings's FCF Margin % distribution charts can be found below:

* The bar in red indicates where NetraMark Holdings's FCF Margin % falls into.

NetraMark Holdings FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

NetraMark Holdings's FCF Margin for the fiscal year that ended in Sep. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Sep. 2023 )	/	Revenue (A: Sep. 2023 )
	=	-2.39	/	0.089
	=	-2,685.39 %

NetraMark Holdings's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-0.958	/	0
	=	%

NetraMark Holdings FCF Margin % Related Terms

Thank you for viewing the detailed overview of NetraMark Holdings's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

NetraMark Holdings (XCNQ:AIAI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » NetraMark Holdings Inc (XCNQ:AIAI) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

AINMF:USA

Address

1655 Dupont Street, Suite 101, Toronto, ON, CAN, M6P 3T1

Website

https://www.nurosene.com

NetraMark Holdings Inc is focused on the application of a totally unique Artificial Intelligence (AI) / Machine Learning (ML) solution targeted at the pharmaceutical industry in order to de-risk clinical trials. NetraMark has a proprietary technology that is capable of cutting through the combinatorial complexity that comes with dealing with heterogeneous patient populations to extract precisely defined personas of patients with respect to placebo and drug response, in addition to tolerability and adverse events. By using the client's own contemporaneous data, and having the capacity to learn from small data, the NetraAI tech extracts these personas to equip pharmaceutical companies with strategies to optimize their next trials for success.

Executives

Andrew Parks

Director

NetraMark Holdings (XCNQ:AIAI) Headlines

No Headlines